ATOSSA THERAPEUTICS, INC.

For the period ended Mar 31, 2026. Filed May 8, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 8, 2026

ATOS$2.14+0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(amounts in thousands)

	For the Three Months Ended March 31,
	2026	2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$(9,589)	$(6,718)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	722	563
Depreciation	4	4
Changes in operating assets and liabilities:
Prepaid materials	68	19
Prepaid expenses and other current assets	(699)	(274)
Other assets	711	(11)
Accounts payable	(1,724)	486
Accrued expenses	1,500	869
Payroll liabilities	(615)	(920)
Other current liabilities	41	23
Net cash used in operating activities	(9,581)	(5,959)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	—	(9)
Net cash used in investing activities	—	(9)
CASH FLOWS FROM FINANCING ACTIVITIES
Net cash provided by financing activities	—	—
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(9,581)	(5,968)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE	41,409	71,194
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	$31,828	$65,226
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents	$31,718	$65,116
Restricted cash	110	110
Total cash, cash equivalents and restricted cash	$31,828	$65,226

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.